The Business Case For Post-Grant Patent Review
Counsels’ view of what inter parte reviews and other new procedures introduced by the America Invents Act mean to the biopharma industry.
You may also be interested in...
For years medical device makers have largely avoided one of the technology world’s biggest headaches: patent “troll” litigation, but that’s about to change. What medtech needs to do to fight the trolls.
Patent review proceedings established by America Invents Act may become ‘close second’ to ANDA litigation as way to invalidate patents; industry calls for changes as patent claims are routinely struck down.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.